Earnings Alerts

Olympus Corp (7733) Earnings Outperform Forecasts: FY Operating Income and Net Sales Exceed Expectations

• Olympus’s fiscal year operating income forecast is 177.00 billion yen, surpassing the estimate of 164.26 billion yen.

• The company’s net income projection is 121.00 billion yen, higher than the 113.71 billion yen estimated.

• Olympus anticipates net sales for the year to reach 1.02 trillion yen, exceeding the estimated 988.64 billion yen.

• It foresees a dividend of 20.00 yen per share, marginally above the estimation of 19.87 yen.

• However, the fourth quarter results showcased a significant drop with operating income at 4.56 billion yen, -90% year-over-year (y/y) and lower than the estimated 20.57 billion yen.

• Net income for Q4 was 7.35 billion yen, representing a decrease of -79% compared to the same period last year and below the estimate of 15.66 billion yen.

• Nevertheless, net sales increased by +8.4% y/y to 260.50 billion yen, slightly above the estimated 255.65 billion yen.

• The Endoscopic Solutions sector posted a revenue of 586.62 billion yen, indicating a +6.3% y/y growth and surpassing the estimate of 579.11 billion yen.

• Therapeutic Solutions revenue amounted to 337.33 billion yen, up by +6% y/y but slightly below the estimated 337.53 billion yen.

• Olympus received 11 buy ratings, 4 hold ratings and no sells from analysts.


Olympus Corp on Smartkarma

Analyst coverage on Olympus Corp on Smartkarma has highlighted concerning developments. Tina Banerjee‘s bearish insight, “Olympus Corp (7733 JP): Q3 Operating Profit Misses Estimates Despite Sales Beat; FY24 Guidance Cut,” reveals that Q3 results were disappointing for Olympus. While revenue surpassed expectations, operating profit declined by 30% year-on-year, leading to a cut in FY24 sales guidance. The company cited the impact of the recent earthquake as a key reason for this downward revision. Although there are hopes for improvement in revenue and profits in FY25, achieving the targeted operating margin and sales growth remains challenging.

Moreover, Michael Fritzell‘s report, “Fraud in Asia,” emphasizes the crucial aspect of assessing corporate governance when considering investments in the region. Fritzell underlines the scarcity of resources on this topic, making navigating the landscape complex. He praises the work of Chinhwee Tan and Tom Robinson on Asian Financial Statement Analysis as valuable in this regard. These insights shed light on important considerations for investors looking at companies like Olympus Corp in the Asian market.


A look at Olympus Corp Smart Scores

FactorScoreMagnitude
Value2
Dividend2
Growth5
Resilience3
Momentum3
OVERALL SMART SCORE3.0

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Olympus Corp has a positive long-term outlook. With a high growth score of 5, the company is expected to experience strong growth potential in the future. This is complemented by moderate scores in resilience and momentum, indicating a stable and steadily growing company. While the value and dividend scores are lower, the strong growth score suggests that investors may benefit from capital appreciation over time.

Olympus Corporation is a leading manufacturer of optoelectronic products, specializing in cameras, video sets, endoscopes for medical and industrial applications, microscopes, and other analytical equipment. The company also offers a range of office communication systems, laseroptical scanners, and ionic printers. With its emphasis on innovation and technology, coupled with a promising growth outlook, Olympus Corp is poised for long-term success in the optoelectronics industry.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars